Skip to search formSkip to main contentSkip to account menu

topiroxostat

Known as: 4-(5-(Pyridin-4-yl)-1h-1,2,4-triazol-3-yl)pyridine-2-carbonitrile 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

FYX-051

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
高尿酸血症患者を対象としたトピロキソスタットの効果検討―SANADA Study―
Background　Recently, hyperuricemia is associated to be a risk factor for not only gouty arthritis but also renal dysfunction and… 
2019
2019
RENAL PROTECTIVE EFFECTS OF TOPIROXOSTAT AND FEBUXISTAT, NEWLY AVAILABLE XANTHINE OXIDASE INHIBITORS
Objective:Control of uric acid level (UA) plays an important role in the protection of organs in hypertensive (HTN) patients… 
2018
2018
Evaluating Safety and efficacy in retrospective ANAlysis after switching Drug to topiroxostat Among patients with hyperuricemia study（SANADA study）
結 果 本研究の解析対象集団は対象基準を満たす 83名とした.なお,結果は average±SDもしく は,median[Q1, Q3]で表示する.Topの 24週間 投与で,本研究の主要評価項目であるL-FABP (μg /g・Cre)は7.6±8.0… 
2017
2017
痛風・高尿酸血症患者に対するトピロキソスタットの使用実態下における安全性および有効性の評価―使用成績調査（18 週時中間報告）より―
Background：Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemia in patients… 
2016
2016
Medicine composition with topiroxostat and application of medicine composition
The invention relates to a medicine composition with topiroxostat and application of the medicine composition, and belongs to the… 
2015
2015
Apoptosis induced by an uromodulin mutant C112Y and its suppression by topiroxostat
BackgroundFamilial juvenile hyperuricemic nephropathy (FJHN) is an autosomal dominant disorder caused by mutations in UMOD that… 
2015
2015
トピロキソスタットの尿酸および尿中アルブミンに与える影響―痛風・高尿酸血症を合併したCKD3 患者を 対象としたプラセボ対照二重盲検試験の併用薬・CKD 原疾患別追加解析―
Background　Chronic kidney disease（CKD）is highly prevalent in hyperuricemic patients. Cardiovascular events╱kidney failure are… 
2015
2015
Process Improvement on the Synthesis of Topiroxostat
2014
2014
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients
2014
2014
Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors
The present study was performed to elucidate the underlying mechanism of transitional cell tumors found in the carcinogenicity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)